Cited by 1,987Cancer-related Molecular PathwaysCell death mechanisms and regulationPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 60 of the 70 references it cites were found in a registry or an index.

The p53 proto-oncogene can act as a suppressor of transformation

Finlay, Cathy A., Hinds, Philip W., Levine, Arnold J.·1989·Cell

Open this paper in CoChat — free account

Abstract

DNA clones of the wild-type p53 proto-oncogene inhibit the ability of E1A plus ras or mutant p53 plus ras-activated oncogenes to transform primary rat embryo fibroblasts. The rare clones of transformed foci that result from E1A plus ras plus wild-type p53 triple transfections all contain the p53 DNA in their genome, but the great majority fail to express the p53 protein. The three cell lines derived from such foci that express p53 all produce mutant p53 proteins with properties similar or identical to transformation-activated p53 proteins. The p53 mutants selected in this fashion (transformation in vitro) resemble the p53 mutants selected in tumors (in vivo). These results suggest that the p53 proto-oncogene can act negatively to block transformation.

Integrity signals

Registry

Crossref · 10.1016/0092-8674(89)90045-7

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,302
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.
Southern, P. J., & Berg, P. R. (1982) · PubMed · Cited by 2,740
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814
Self-citation
SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene
DeCaprio, J. A., Ludlow, J. W., Figge, J., Shew, J.-Y., Huang, C.-M., Lee, W.-H., Marsilio, E., Paucha, E., & Livingston, D. M. (1988) · Cell · doi:10.1016/0092-8674(88)90559-4 · Cited by 1,459
Human Retinoblastoma Susceptibility Gene: Cloning, Identification, and Sequence
Lee, W., Bookstein, R., Hong, F., Young, L.-J., Shew, J., & Lee, E. Y.-H. P. (1987) · Science · doi:10.1126/science.3823889 · Cited by 1,417
Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product
Whyte, P., Buchkovich, K. J., Horowitz, J. M., Friend, S. H., Raybuck, M., Weinberg, R. A., & Harlow, E. (1988) · Nature · doi:10.1038/334124a0 · Cited by 1,403
Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture
Ruley, H. E. (1983) · Nature · doi:10.1038/304602a0 · Cited by 1,248

Show all 70 references

Sorted by citations

Items 101–200 of 999

Accumulation of p53 protein correlates with a poor prognosis in human lung cancer.
Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., & Doshi, H. M. (1992) · PubMed · Cited by 383
The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T
Ludlow, J. W., Shon, J. C., Pipas, J. M., Livingston, D. M., & DeCaprio, J. A. (1990) · Cell · doi:10.1016/0092-8674(90)90590-b · Cited by 381
Germline Mutations of the p53 Tumor-Suppressor Gene in Children and Young Adults with Second Malignant Neoplasms
Malkin, D. M., Jolly, K. W., Barbier, N., Look, A. T., Friend, S. H., Gebhardt, M. C., Andersen, T. I., Børresen‐Dale, A., Li, F. P., Garber, J. E., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262002 · Cited by 378
MOLECULAR MECHANISMS OF ULTRAVIOLET RADIATION CARCINOGENESIS
Ananthaswamy, H. N., & Pierceall, W. E. (1990) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1990.tb08452.x · Cited by 374
Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease
Butel, J. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.405 · Cited by 368
Targeting the MDM2-p53 Interaction for Cancer Therapy
Shangary, S. K., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 372
Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication
Bargonetti, J., Friedman, P. N., Kern, S. E., Vogelstein, B., & Prives, C. L. (1991) · Cell · doi:10.1016/0092-8674(91)90560-l · Cited by 367
The transcriptional transactivation function of wild‐type p53 is inhibited by SV40 large T‐antigen and by HPV‐16 E6 oncoprotein.
Mietz, J. A., Unger, T., Huibregtse, J. M., & Howley, P. M. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05608.x · Cited by 366
NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress.
Wu, H., & Lozano, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32128-2 · Cited by 359
Li-Fraumeni syndrome – a molecular and clinical review
Varley, J. M., Evans, D. G., & Birch, J. M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.328 · Cited by 361
Inhibition of Cyclooxygenase-2 Gene Expression by p53
Subbaramaiah, K., Altorki, N. K., Chung, W. J., MESTRE, J. R., Sampat, A., & Dannenberg, A. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10911 · Cited by 355
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V., Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 362
p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
Lehman, T. A., Bennett, W. P., Metcalf, R. A., Welsh, J. A., Ecker, J., Modali, R. V., Ullrich, S. J., Romano, J. W., Appella, E., & Testa, J. R. (1991) · PubMed · Cited by 349
Nuclear Accumulation of p53 Protein Is Mediated by Several Nuclear Localization Signals and Plays a Role in Tumorigenesis
Shaulsky, G., Goldfinger, N., Ben‐Ze'ev, A., & Rotter, V. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6565-6577.1990 · Cited by 346
Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.
Bischoff, J. R., Friedman, P. N., Marshak, D. R., Prives, C. L., & Beach, D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4766 · Cited by 342
Identification of a Minimal Transforming Domain of p53: Negative Dominance through Abrogation of Sequence-Specific DNA Binding
Shaulian, E., Zauberman, A., Ginsberg, D., & Oren, M. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5581 · Cited by 343
Degradation of nuclear oncoproteins by the ubiquitin system in vitro.
Ciechanover, A. J., DiGiuseppe, J. A., Bercovich, B., Orian, A., Richter, J. D., Schwartz, A. L., & Brodeur, G. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.1.139 · Cited by 336
CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest.Preprint
Barone, M. V., Crozat, A., Tabaee, A., Philipson, L., & Ron, D. (1994) · Genes & Development · doi:10.1101/gad.8.4.453 · Cited by 336
The tumore suppressor p53
Donehower, L. A., & Bradley, A. (1993) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(93)90004-v · Cited by 334
Pancreatic adenocarcinomas frequently show p53 gene mutations.
Scarpa, A., Capelli, P., Mukai, K., Zamboni, G., Oda, T., Iacono, C., & Hirohashi, S. (1993) · PubMed Central · Cited by 332
Tumor-Suppressor Functions of the TP53 PathwayPreprint
Aubrey, B. J., Strasser, A., & Kelly, G. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026062 · Cited by 352
Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53
Mack, D. H., Vartikar, J., Pipas, J. M., & Laimins, L. A. (1993) · Nature · doi:10.1038/363281a0 · Cited by 322
p53 expression and prognosis in gastric carcinoma
Martin, H. M., Filipe, M. I., Morris, R. W., Lane, D. P., & Silvestre, F. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500604 · Cited by 321
The Ribosomal L5 Protein Is Associated with mdm-2 and mdm-2-p53 Complexes
Maréchal, V., Elenbaas, B., Piette, J., Nicolas, J. C., & Levine, A. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7414 · Cited by 318
Self-citation
ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors
Zaika, A., Slade, N., Erster, S. H., Sansome, C., Joseph, T. W., Pearl, M. L., Chalas, E., & Moll, U. M. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020179 · Cited by 316
Frequent Mutations in the p53 Tumor Suppressor Gene in Human Leukemia T-Cell Lines
Cheng, J. F., & Haas, M. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.10.5502-5509.1990 · Cited by 318
LOSS OF CONSTITUTIONAL HETEROZYGOSITY IN HUMAN CANCER
Lasko, D. D., Cavenee, W. K., & Nordenskjöld, M. (1991) · Annual Review of Genetics · doi:10.1146/annurev.ge.25.120191.001433 · Cited by 314
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Finlay, C. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.301 · Cited by 311
Self-citation
Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element.Preprint
Zambetti, G. P., Bargonetti, J., Walker, K. K., Prives, C. L., & Levine, A. J. (1992) · Genes & Development · doi:10.1101/gad.6.7.1143 · Cited by 311
Self-citation
Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor Prognosis
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308
p53 and MicroRNA-34 Are Suppressors of Canonical Wnt Signaling
Kim, N. H., Kim, N.-G., Kim, N.-G., Lee, I., Choi, H.-S., Li, X.-Y., Kang, S. E., Cha, S. Y., Ryu, J. K., Na, J. M., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001744 · Cited by 311
Role of Cysteine Residues in Regulation of p53 Function
Rainwater, R., Parks, D., Anderson, M. E., Tegtmeyer, P., & Mann, K. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3892 · Cited by 306
Alternative splicing in cancer: implications for biology and therapy
Chen, J., & Weiss, W. A. (2014) · Oncogene · doi:10.1038/onc.2013.570 · Cited by 309
Prevalence and Spectrum of Germline Mutations of the p53 Gene among Patients with Sarcoma
Toguchida, J., Yamaguchi, T., Dayton, S. H., Beaughamp, R. L., Herrera, G. E., Ishizaki, K., Yamamuro, T., Meyers, P. A., Little, J. B., Sasaki, M. S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262001 · Cited by 304
The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system.
Moser, A. R., Dove, W. F., Roth, K. A., & Gordon, J. I. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.116.6.1517 · Cited by 304
The cell cycle and the retinoblastoma protein family
Ewen, M. E. (1994) · Cancer and Metastasis Reviews · doi:10.1007/bf00690418 · Cited by 305
Human TAFII31 protein is a transcriptional coactivator of the p53 protein.
Lu, H., & Levine, A. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.5154 · Cited by 301
Self-citation
Regulation of the Human hsp70 Promoter by p53
Agoff, S. N., Hou, J., Linzer, D. I., & Wu, B. (1993) · Science · doi:10.1126/science.8418500 · Cited by 292
Mutation spectrum of the p53 gene in bone and soft tissue sarcomas.
Toguchida, J., Yamaguchi, T., Ritchie, B., Beauchamp, R. L., Dayton, S. H., Herrera, G. E., Yamamuro, T., Kotoura, Y., Sasaki, M. S., & Little, J. B. (1992) · PubMed · Cited by 297
Two distinctp53 immunohistochemical patterns in human squamous-cell skin cancer, precursors and normal epidermis
Ren, Z.-P., Pontén, F., Nistér, M., & Pontén, I. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960621)69:3 · Cited by 98
Sex steroidal regulation of uterine leiomyoma growth and apoptosis
Maruo, T. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh019 · Cited by 292
p53 gene mutations and protein accumulation in human ovarian cancer.
Kupryjańczyk, J., Thor, A. D., Beauchamp, R. L., Merritt, V., Edgerton, S. M., Bell, D. A., & Yandell, D. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.4961 · Cited by 289
PML, a Growth Suppressor Disrupted in Acute Promyelocytic Leukemia
Mu, Z. M., Chin, K., Liu, H., Lozano, G., & Chang, K. S. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6858 · Cited by 288
Genetic background alters the spectrum of tumors that develop in p53‐deficient mice
Harvey, M., McArthur, M. J., Montgomery, C. A., Bradley, A., & Donehower, L. A. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344491 · Cited by 285
Genetic basis for p53 overexpression in human breast cancer.
Davidoff, A. M., Humphrey, P. A., Iglehart, J. D., & Marks, J. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.5006 · Cited by 284
COMMENTARY: p53 Tumor suppressor gene: from the basic research laboratory to the clinic—an abridged historical perspective
Harris, C. C. (1996) · Carcinogenesis · doi:10.1093/carcin/17.6.1187 · Cited by 291
Li-Fraumeni syndrome: cancer risk assessment and clinical management
McBride, K. A., Ballinger, M. L., Killick, E., Kirk, J., Tattersall, M. H. N., Eeles, R. A., Thomas, D. M., & Mitchell, G. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.41 · Cited by 286
To die or not to die: how does p53 decide?
Slee, E. A., O’Connor, D. J., & Lü, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207516 · Cited by 282
Accumulation of p53 in a Mutant Cell Line Defective in the Ubiquitin Pathway
Chowdary, D., Dermody, J. J., Jha, K. K., & Ozer, H. L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1997 · Cited by 277
The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II.
Meek, D. W., Simon, S., Kikkawa, U., & Eckhart, W. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07524.x · Cited by 277
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma
Barrans, S., Carter, I. W. J., Owen, R. G., Davies, F. E., Patmore, R. D., Haynes, A., Morgan, G. J., & Jack, A. (2002) · Blood · doi:10.1182/blood.v99.4.1136 · Cited by 276
The nuclear tyrosine kinase c-abl negatively regulates cell growth
Sawyers, C. L., McLaughlin, J., Goga, A., Havlik, M., & Witte, O. N. (1994) · Cell · doi:10.1016/0092-8674(94)90240-2 · Cited by 277
Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase.
Lin, D., Shields, M. T., Ullrich, S. J., Appella, E., & Mercer, W. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9210 · Cited by 267
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53‐mediated repression of transcription.
Lechner, M. S., Mack, D. H., Finicle, A. B., Crook, T., Vousden, K. H., & Laimins, L. A. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05375.x · Cited by 272
Mechanisms of p53 loss in human sarcomas.
Mulligan, L. M., Matlashewski, G., Scrable, H. J., & Cavenee, W. K. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.15.5863 · Cited by 268
Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson, M. C., Dietrich, K. D., Danyluk, J., Paterson, A. H., LEES, A. W., Jamil, N. S. M., Hanson, J., Jenkins, H., Krause, B. E., & McBlain, W. A. (1991) · PubMed · Cited by 264
Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours
Jaros, E., Perry, R. H., Adam, L., Kelly, P. J., Crawford, P. J., Kalbag, R. M., Mendelow, A. D., Sengupta, R., & Pearson, A. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.273 · Cited by 264
Genetic changes in skin tumor progression: Correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7
Bremner, R., & Balmain, A. (1990) · Cell · doi:10.1016/0092-8674(90)90523-h · Cited by 264
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 267
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.
Unger, T., Nau, M. M., Segal, S., & Minna, J. D. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05183.x · Cited by 261
HUMAN TUMOR SUPPRESSOR GENES
Stanbridge, E. J. (1990) · Annual Review of Genetics · doi:10.1146/annurev.ge.24.120190.003151 · Cited by 264
The p53 Activation Domain Binds the TATA Box-Binding Polypeptide in Holo-TFIID, and a Neighboring p53 Domain Inhibits Transcription
Liu, X. E., Miller, C. W., Koeffler, H. P., & Berk, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.6.3291-3300.1993 · Cited by 260
p53 gene mutations in Barrett's epithelium and esophageal cancer.
Casson, A. G., Mukhopadhyay, T., Cleary, K. R., Ro, J. Y., Levin, B., & Roth, J. A. (1991) · PubMed · Cited by 257
Smoking, p53 Mutation, and Lung Cancer
Gibbons, D. L., Byers, L. A., & Kurie, J. M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0539 · Cited by 255
Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue.
Porter, P. L., Gown, A. M., Kramp, S. G., & Coltrera, M. D. (1992) · PubMed Central · Cited by 255
p53 is frequently mutated in Burkitt's lymphoma cell lines
Farrell, P. J., Allan, G. J., Shanahan, F., Vousden, K. H., & Crook, T. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07837.x · Cited by 254
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.
Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G. J., Zhang, Z., Schultz, P., Cordon‐Cardo, C., & Scher, H. I. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1384 · Cited by 254
The p53 family: guardians of maternal reproduction
Levine, A. J., Tomasini, R., McKeon, F., Mak, T. W., & Melino, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3086 · Cited by 260
Self-citation
Over‐expression of p53 nuclear oncoprotein in transitional‐cell bladder cancer and its prognostic value
Lipponen, P. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530304 · Cited by 252
Targeting p53 for Novel Anticancer Therapy
Wang, Z., & Sun, Y. (2010) · Translational Oncology · doi:10.1593/tlo.09250 · Cited by 256
The History of Tumor Virology
Javier, R. T., & Butel, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-3301 · Cited by 258
Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression.
Mercer, W. E., Shields, M. T., Lin, D. P., Appella, E., & Ullrich, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.5.1958 · Cited by 248
Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck
Field, J. K., Spandidos, D. A., Malliri, A., Gosney, J. R., Yiagnisis, M., & Stell, P. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.352 · Cited by 247
HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis
Lan, K., Sheu, M., Hwang, S., Yen, S., Chen, S., Wu, J., Wang, Y.-J., Kato, N., Omata, M., Chang, F., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205589 · Cited by 252
Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer
Bell, S. M., Scott, N., Cross, D., Sagar, P. M., Lewis, F. A., Blair, G. E., Taylor, G. R., Dixon, M. F., & Quirke, P. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90835-z · Cited by 244
Tumor Suppressor p53: Analysis of Wild-Type and Mutant p53 Complexes
Milner, J., Medcalf, E., & Cook, A. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.12 · Cited by 243
p53 expression in colorectal tumors.
Purdie, C. A., O’Grady, J., Piris, J., Wyllie, A. H., & Bird, C. (1991) · PubMed Central · Cited by 240
Maintenance of p53 alterations throughout breast cancer progression.
Davidoff, A. M., Kerns, B. J., Iglehart, J. D., & Marks, J. R. (1991) · PubMed · Cited by 237
p53 domains: identification and characterization of two autonomous DNA-binding regions.Preprint
Wang, Y., Reed, M. J., Wang, P., Stenger, J. E., Mayr, G. A., Anderson, M. E., Schwedes, J. F., & Tegtmeyer, P. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2575 · Cited by 239
An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control
Gualberto, A., Aldape, K., Kozakiewicz, K., & Tlsty, T. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5166 · Cited by 241
Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activities
Halevy, O., Michalovitz, D., & Oren, M. (1990) · Science · doi:10.1126/science.2218501 · Cited by 234
Transcriptional activation by p53 correlates with suppression of growth but not transformation
Crook, T. J. (1994) · Cell · doi:10.1016/0092-8674(94)90071-x · Cited by 229
Overexpression and mutation of p53 in endometrial carcinoma.
Kohler, M. F., Berchuck, A., Davidoff, A. M., Humphrey, P., Rk, D., Jd, I., Jt, S., Clarke-Pearson, D., Bast, R. C., & Маркс (1992) · PubMed · Cited by 229
A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient mice
Harvey, M., Vogel, H. S., Morris, D. K., Bradley, A., Bernstein, A., & Donehower, L. A. (1995) · Nature Genetics · doi:10.1038/ng0395-305 · Cited by 232
Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis.
Tamura, G., Kihana, T., Nomura, K., Terada, M., Sügimura, T., & Hirohashi, S. (1991) · PubMed · Cited by 228
An N-Terminal transformation-governing sequence of SV40 large T antigen contributes to the binding of both p110 and a second cellular protein, p120
Ewen, M. E., Ludlow, J. W., Marsilio, E., DeCaprio, J. A., Millikan, R. C., Cheng, S. H., Paucha, E., & Livingston, D. M. (1989) · Cell · doi:10.1016/0092-8674(89)90840-4 · Cited by 228
Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system
Ohgaki, H., Eibl, R. H., Reichel, M., Mariani, L., Petersen, I., Holl, T. M., Wiestler, O. D., Kleihues, P., Schwab, M., & Gehring, M. (1993) · Molecular Carcinogenesis · doi:10.1002/mc.2940080203 · Cited by 226
Prognostic significance of p53 overexpression in gastric and colorectal carcinoma
Starzyñska, T., Bromley, M., Ghosh, A. K., & Stern, P. L. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.314 · Cited by 226
The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth
Cadwell, C., & Zambetti, G. P. (2001) · Gene · doi:10.1016/s0378-1119(01)00696-5 · Cited by 231
Precancerous Lesions of the Cervix
Wright, T. C., Kurman, R. J., & Ferenczy, A. S. (1994) · Springer eBooks · doi:10.1007/978-1-4757-3889-6_7 · Cited by 222
Mutations in p53 as potential molecular markers for human breast cancer.
Runnebaum, I. B., Nagarajan, M., Bowman, M. E., Soto, D., & Sukumar, S. V. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10657 · Cited by 222
Negative regulation of bcl-2 expression by p53 in hematopoietic cells
Wu, Y.-L., Mehew, J. W., Heckman, C. A., Arcinas, M., & Boxer, L. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204067 · Cited by 221
p53 in chronic myelogenous leukemia in acute phase.
Feinstein, E., Cimino, G. G., Rp, G., Alimena, G., Berthier, R., Kishi, K., Goldman, J. M., Zaccaria, A., Berrebi, A., & Canaani, E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6293 · Cited by 220
Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.
Diller, L., Sexsmith, E., Gottlieb, A., Li, F. P., & Malkin, D. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117834 · Cited by 218
Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity
Shi, D., & Gu, W. J. (2012) · Genes & Cancer · doi:10.1177/1947601912455199 · Cited by 220
Essential role for p53-mediated transcription in E1A-induced apoptosis.Preprint
Sabbatini, P., Lin, J., Levine, A. J., & White, E. (1995) · Genes & Development · doi:10.1101/gad.9.17.2184 · Cited by 215
Self-citation
Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53
Wang, Y., Yang, L., Zhang, X., Cui, W., Liu, Y., Sun, Q., He, Q., Zhao, S., Zhang, G., Wang, Y., et al. (2019) · EMBO Reports · doi:10.15252/embr.201847563 · Cited by 215
Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines.
Yaginuma, Y., & Westphal, H. (1992) · PubMed · Cited by 214
Frequent mutations in the p53 gene in human myeloid leukemia cell lines
Sugimoto, K., Toyoshima, H., Sakai, R., Miyagawa, K., Hagiwara, K., Ishikawa, F., Takaku, F., Yazaki, Y., & Hirai, H. (1992) · Blood · doi:10.1182/blood.v79.9.2378.2378 · Cited by 213
The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53
Levine, A. J. (2008) · Virology · doi:10.1016/j.virol.2008.09.034 · Cited by 212
Self-citation

Authors: Finlay, C. A., Hinds, P. W., & Levine, A. J.
Affiliations: Princeton University (US)
ORCID: Hinds, Philip W.
Levine, Arnold J.
Venue: Cell
Publisher: Elsevier BV
Published: 1989-06
Volume: 57
Issue: 7
Pages: 1083-1093
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/0092-8674(89)90045-7
OpenAlex: W2163565167
Cited by: 1,987
References: 70
Citations by year: 2026: 14 · 2025: 12 · 2024: 25 · 2023: 27 · 2022: 20 · 2021: 34 · 2020: 37 · 2019: 31 · 2018: 29 · 2017: 29 · 2016: 28 · 2015: 12 · 2014: 28 · 2013: 26 · 2012: 38
FWCI: 79.38
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P01CA041086, P01-CA41086-03)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: tumor suppressor, oncogenic transformation, adenovirus E1A, oncogenic Ras, mutant p53, p53 expression, rat embryo fibroblasts, transformed foci, tumor suppressor function
MeSH terms: Animals, Antigens, Polyomavirus Transforming, Cell Line, Cell Transformation, Neoplastic, Cells, Cultured, Gene Expression Regulation, Neoplasm Proteins, Oncogene Proteins, Viral, Phosphoproteins, Proto-Oncogene Proteins, Genes, ras, Transfection, Tumor Suppressor Protein p53, Adenovirus Early Proteins, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The p53 proto-oncogene can act as a suppressor of transformation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks